At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year: 77%, 58%, 40% and 24% achieved last assigned dosing intervals of ≥3, ≥4, ≥5 and 6 months, respectively
At three years, the vast majority of patients who switched to EYLEA HD from a fixed 2-month dosing regimen with EYLEA® (aflibercept) Injection 2 mg maintained visual and anatomic improvements while rapidly extending their dosing intervals: 79%, 43% and 16% achieved last assigned dosing intervals of ≥3, ≥4 and ≥5 months, respectively
Results add to growing body of evidence showing ability of EYLEA HD to extend dosing intervals, including previously presented data in diabetic macular edema following three years of EYLEA HD treatment in which 88%, 68%, 48% and 28% of patients achieved a last assigned dosing interval of ≥3, ≥4, ≥5 and 6 months, respectively
TARRYTOWN, NY, USA I February 08, 2025 I Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive three-year (156-week) results for EYLEA HD® (aflibercept) Injection 8 mg in patients with wet age-related macular degeneration (wAMD) from an extension study of the Phase 3 PULSAR trial. The results were presented today at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) 2025 annual meeting. Similar to the three-year results for the pivotal PHOTON trial in diabetic macular edema (DME), the longer-term wAMD data demonstrated the vast majority of EYLEA HD patients who entered the extension study sustained the visual gains and anatomic improvements achieved by the end of the second year, while also achieving substantially longer treatment intervals. Additionally, patients who switched from EYLEA® (aflibercept) Injection 2 mg to EYLEA HD at the beginning of the third year were also able to maintain vision and anatomic improvements through the end of the third year, but with longer dosing intervals and fewer injections.
“Patients with wet age-related macular degeneration are older and often need assistance in getting to their doctors’ offices. Reducing their treatment burden can be transformative for their care,” said W. Lloyd Clark, M.D., Palmetto Retinal Center, and Assistant Clinical Professor of Ophthalmology at the University of South Carolina School of Medicine. “Impressively, the latest three-year EYLEA HD results show a substantial portion of patients were able to sustain visual and anatomic benefits with only two doses a year. This adds yet another notable piece of evidence to an already remarkable body of data supporting EYLEA HD.”
In PULSAR, EYLEA HD patients were initially randomized at baseline to either 3- or 4-month dosing intervals (after three initial monthly doses). If pre-specified criteria were met, dosing intervals could be shortened throughout the trial or extended in the second and third years. As previously presented, 88% of all EYLEA HD patients maintained ≥3-month dosing intervals at the end of two years. Patients could then participate in an optional extension study for an additional 60 weeks. Of the EYLEA HD patients (n=375) who completed the full 3 years of treatment:
- Nearly 60% had a last assigned dosing interval of ≥4 months, with 40% and 24% having a last assigned dosing interval of ≥5 and 6 months, respectively, at the end of three years of treatment.
- Vision gains and anatomical improvements – including robust reductions in retinal thickness – that were achieved through year two were sustained through year three in the extension study.
Patients in the PULSAR comparator arm received EYLEA as a fixed 2-month dosing regimen (after three initial monthly doses) for 96 weeks. These patients had the option to enter the extension study at week 96 and were switched to a 3-month dosing interval with EYLEA HD. Of these patients who completed the extension study (n=186), vision and anatomic improvements were maintained after switching to EYLEA HD, with 79% and 43% having a last assigned dosing interval of ≥3 and ≥4 months, respectively, at week 156.
The safety profile of EYLEA HD continued to be similar to EYLEA through three years and remained generally consistent with the known safety profile of EYLEA HD in its pivotal trials. Ocular treatment emergent adverse events (TEAEs) occurring in ≥4% of all patients included cataract, retinal hemorrhage, reduction of visual acuity, vitreous floaters, and increase of intraocular pressure. The rate of intraocular inflammation was 2.4% for the patients that switched from EYLEA to EYLEA HD, and 1.9% for the EYLEA HD patients randomized at baseline.
The three-year data from the PHOTON trial for EYLEA HD in DME were previously presented at the American Academy of Ophthalmology annual meeting in October 2024.
EYLEA HD (known as Eylea™ 8 mg in the European Union and Japan) is being jointly developed by Regeneron and Bayer AG. In the U.S., Regeneron maintains exclusive rights to EYLEA and EYLEA HD. Bayer has licensed the exclusive marketing rights outside of the U.S., where the companies share equally the profits from sales of EYLEA and EYLEA HD.
About the EYLEA HD Clinical Trial Program
PULSAR in wAMD and PHOTON in DME/diabetic retinopathy (DR) are double-masked, active-controlled pivotal trials that were conducted in multiple centers globally. In both trials, patients were randomized into 3 treatment groups to receive either: EYLEA HD every 3 months, EYLEA HD every 4 months, or EYLEA every 2 months. The lead sponsors of the trials were Bayer for PULSAR and Regeneron for PHOTON.
Patients treated with EYLEA HD in both trials had 3 initial monthly doses, and patients treated with EYLEA received 3 initial doses in PULSAR and 5 in PHOTON. In the first year, patients in the EYLEA HD groups could have their dosing intervals shortened down to an every 2-month interval if protocol-defined criteria for disease progression were observed. Intervals could not be extended until the second year of the trial. Patients in all EYLEA groups maintained a fixed 2-month dosing regimen throughout their participation in the two-year trials.
In both trials, there was an optional extension study starting at week 96, with all participating patients receiving EYLEA HD through week 156. Patients initially randomized to EYLEA in PULSAR, were switched to EYLEA HD at the start of the extension study and immediately assigned to a 3-month dosing interval. Dosing intervals for all patients in the extension study could be shortened or extended by 2-week increments if protocol-defined criteria were met, with a minimum dosing interval of every 2 months and a maximum dosing interval of every 6 months.
About wAMD and Diabetic Eye Disease
wAMD is a retinal disease that may affect people as they age. It occurs when abnormal blood vessels grow and leak fluid under the macula, the part of the eye responsible for sharp central vision and seeing fine detail. This fluid can damage and scar the macula, which can cause vision loss. An estimated 1.4 million Americans have wAMD.
DR is an eye disease characterized by microvascular damage to the blood vessels in the retina often caused by poor blood sugar control in people with diabetes. The disease generally starts as nonproliferative diabetic retinopathy (NPDR) and often has no warning signs or symptoms. NPDR may progress to proliferative diabetic retinopathy (PDR), a stage of the disease in which abnormal blood vessels grow onto the surface of the retina and into the vitreous cavity, potentially causing severe vision loss.
DME can occur at any stage of DR as the blood vessels in the retina become increasingly fragile and leak fluid, potentially causing visual impairment. In the U.S., approximately 1.5 million adults are diagnosed with DME, while approximately 6 million people have DR without DME.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
INDICATIONS
EYLEA HD® (aflibercept) Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).
EYLEA® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Retinopathy of Prematurity (ROP) (0.4 mg).
Please click here for full Prescribing Information for EYLEA HD and EYLEA.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
SOURCE: Regeneron Pharmaceuticals
Post Views: 193
At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year: 77%, 58%, 40% and 24% achieved last assigned dosing intervals of ≥3, ≥4, ≥5 and 6 months, respectively
At three years, the vast majority of patients who switched to EYLEA HD from a fixed 2-month dosing regimen with EYLEA® (aflibercept) Injection 2 mg maintained visual and anatomic improvements while rapidly extending their dosing intervals: 79%, 43% and 16% achieved last assigned dosing intervals of ≥3, ≥4 and ≥5 months, respectively
Results add to growing body of evidence showing ability of EYLEA HD to extend dosing intervals, including previously presented data in diabetic macular edema following three years of EYLEA HD treatment in which 88%, 68%, 48% and 28% of patients achieved a last assigned dosing interval of ≥3, ≥4, ≥5 and 6 months, respectively
TARRYTOWN, NY, USA I February 08, 2025 I Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive three-year (156-week) results for EYLEA HD® (aflibercept) Injection 8 mg in patients with wet age-related macular degeneration (wAMD) from an extension study of the Phase 3 PULSAR trial. The results were presented today at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) 2025 annual meeting. Similar to the three-year results for the pivotal PHOTON trial in diabetic macular edema (DME), the longer-term wAMD data demonstrated the vast majority of EYLEA HD patients who entered the extension study sustained the visual gains and anatomic improvements achieved by the end of the second year, while also achieving substantially longer treatment intervals. Additionally, patients who switched from EYLEA® (aflibercept) Injection 2 mg to EYLEA HD at the beginning of the third year were also able to maintain vision and anatomic improvements through the end of the third year, but with longer dosing intervals and fewer injections.
“Patients with wet age-related macular degeneration are older and often need assistance in getting to their doctors’ offices. Reducing their treatment burden can be transformative for their care,” said W. Lloyd Clark, M.D., Palmetto Retinal Center, and Assistant Clinical Professor of Ophthalmology at the University of South Carolina School of Medicine. “Impressively, the latest three-year EYLEA HD results show a substantial portion of patients were able to sustain visual and anatomic benefits with only two doses a year. This adds yet another notable piece of evidence to an already remarkable body of data supporting EYLEA HD.”
In PULSAR, EYLEA HD patients were initially randomized at baseline to either 3- or 4-month dosing intervals (after three initial monthly doses). If pre-specified criteria were met, dosing intervals could be shortened throughout the trial or extended in the second and third years. As previously presented, 88% of all EYLEA HD patients maintained ≥3-month dosing intervals at the end of two years. Patients could then participate in an optional extension study for an additional 60 weeks. Of the EYLEA HD patients (n=375) who completed the full 3 years of treatment:
- Nearly 60% had a last assigned dosing interval of ≥4 months, with 40% and 24% having a last assigned dosing interval of ≥5 and 6 months, respectively, at the end of three years of treatment.
- Vision gains and anatomical improvements – including robust reductions in retinal thickness – that were achieved through year two were sustained through year three in the extension study.
Patients in the PULSAR comparator arm received EYLEA as a fixed 2-month dosing regimen (after three initial monthly doses) for 96 weeks. These patients had the option to enter the extension study at week 96 and were switched to a 3-month dosing interval with EYLEA HD. Of these patients who completed the extension study (n=186), vision and anatomic improvements were maintained after switching to EYLEA HD, with 79% and 43% having a last assigned dosing interval of ≥3 and ≥4 months, respectively, at week 156.
The safety profile of EYLEA HD continued to be similar to EYLEA through three years and remained generally consistent with the known safety profile of EYLEA HD in its pivotal trials. Ocular treatment emergent adverse events (TEAEs) occurring in ≥4% of all patients included cataract, retinal hemorrhage, reduction of visual acuity, vitreous floaters, and increase of intraocular pressure. The rate of intraocular inflammation was 2.4% for the patients that switched from EYLEA to EYLEA HD, and 1.9% for the EYLEA HD patients randomized at baseline.
The three-year data from the PHOTON trial for EYLEA HD in DME were previously presented at the American Academy of Ophthalmology annual meeting in October 2024.
EYLEA HD (known as Eylea™ 8 mg in the European Union and Japan) is being jointly developed by Regeneron and Bayer AG. In the U.S., Regeneron maintains exclusive rights to EYLEA and EYLEA HD. Bayer has licensed the exclusive marketing rights outside of the U.S., where the companies share equally the profits from sales of EYLEA and EYLEA HD.
About the EYLEA HD Clinical Trial Program
PULSAR in wAMD and PHOTON in DME/diabetic retinopathy (DR) are double-masked, active-controlled pivotal trials that were conducted in multiple centers globally. In both trials, patients were randomized into 3 treatment groups to receive either: EYLEA HD every 3 months, EYLEA HD every 4 months, or EYLEA every 2 months. The lead sponsors of the trials were Bayer for PULSAR and Regeneron for PHOTON.
Patients treated with EYLEA HD in both trials had 3 initial monthly doses, and patients treated with EYLEA received 3 initial doses in PULSAR and 5 in PHOTON. In the first year, patients in the EYLEA HD groups could have their dosing intervals shortened down to an every 2-month interval if protocol-defined criteria for disease progression were observed. Intervals could not be extended until the second year of the trial. Patients in all EYLEA groups maintained a fixed 2-month dosing regimen throughout their participation in the two-year trials.
In both trials, there was an optional extension study starting at week 96, with all participating patients receiving EYLEA HD through week 156. Patients initially randomized to EYLEA in PULSAR, were switched to EYLEA HD at the start of the extension study and immediately assigned to a 3-month dosing interval. Dosing intervals for all patients in the extension study could be shortened or extended by 2-week increments if protocol-defined criteria were met, with a minimum dosing interval of every 2 months and a maximum dosing interval of every 6 months.
About wAMD and Diabetic Eye Disease
wAMD is a retinal disease that may affect people as they age. It occurs when abnormal blood vessels grow and leak fluid under the macula, the part of the eye responsible for sharp central vision and seeing fine detail. This fluid can damage and scar the macula, which can cause vision loss. An estimated 1.4 million Americans have wAMD.
DR is an eye disease characterized by microvascular damage to the blood vessels in the retina often caused by poor blood sugar control in people with diabetes. The disease generally starts as nonproliferative diabetic retinopathy (NPDR) and often has no warning signs or symptoms. NPDR may progress to proliferative diabetic retinopathy (PDR), a stage of the disease in which abnormal blood vessels grow onto the surface of the retina and into the vitreous cavity, potentially causing severe vision loss.
DME can occur at any stage of DR as the blood vessels in the retina become increasingly fragile and leak fluid, potentially causing visual impairment. In the U.S., approximately 1.5 million adults are diagnosed with DME, while approximately 6 million people have DR without DME.
IMPORTANT SAFETY INFORMATION AND INDICATIONS
INDICATIONS
EYLEA HD® (aflibercept) Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).
EYLEA® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Retinopathy of Prematurity (ROP) (0.4 mg).
Please click here for full Prescribing Information for EYLEA HD and EYLEA.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
SOURCE: Regeneron Pharmaceuticals
Post Views: 193
